PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Bladder neoplasm

Drugs in development · updated 30 October 2026

Bladder neoplasm: drugs in development

As of 30 October 2026 there are 207 active clinical trials (recruiting or ongoing, phases I–III) on 185 drugs for bladder neoplasm. 98 are experimental, that is not yet approved in the United States.

207Active trials
98Experimental drugs
12Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
Disitamab VedotinRC48-ADC, Disitamb VedotinII–III7NCT07756008
CetrelimabJNJ-63723283III3NCT05714202
TAR-200III3NCT05714202
VepugratinibIII3NCT07218380
Sacituzumab TirumotecanSKB264III2NCT07419295
TARA-002III2NCT07480356
FE 999326III1NCT05704244
NDV01III1NCT07464145
PF-06801591III1NCT04165317
RilvegostomigAZD2936III1NCT07720284
UGN-102III1NCT05243550
VinflunineJavlor®III1NCT07419295
CamrelizumabCarrelizumab, CarilizumabI–II2NCT04706598
EntinostatEnitinostatI–II2NCT07261592
Intismeran autogenemRNA-4157I–II2NCT06305767
MK-3120I–II2NCT07222488
SapanisertibII2NCT02465060
SasanlimabZumrad®II2NCT05241340
Zelenectide pevedotinBT8009I–II2NCT04561362
ZimberelimabAB122, GLS-010II2NCT06528483
[18F]FAPI-74II1NCT06503146
AdavosertibAZD1775II1NCT02465060
AdebrelimabSHR-1316, AdebelimabII1NCT06091124
ASG-22CEII1NCT05879653
AU-007I–II1NCT05267626
BAY2927088II1NCT06760819
BDB001EIK1001II1NCT03915678
BH011I–II1NCT06732531
CP-383I–II1NCT07030257
EBNK-001I–II1NCT07410676
EG-70I–II1NCT04752722
FexagratinibAZD4547II1NCT02465060
FianlimabREGN3767II1NCT06571708
GuadecitabineII1NCT03179943
HMBD-001I–II1NCT05057013
HTL0039732I–II1NCT05944237
IAP0971I–II1NCT06255964
IL-15I–II1NCT07410676
IpatasertibII1NCT02465060
IvonescimabAK112I–II1NCT06957561

Sorted by most advanced phase and number of active trials. Showing 40 of 98 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
GemcitabineGemcitabin, GemzarII–III47NCT07129993
PembrolizumabKEYTRUDA, MK-3475III43NCT07566156
CisplatinCis Platinum, CisplatineII–III36NCT07129993
Enfortumab VedotinPadcev®III18NCT07566156
NivolumabOpdivo, ONO-4538III17NCT07720284
DurvalumabMEDI4736, Imfinzi®III15NCT03732677
AtezolizumabTecentriq, MPDL3280AIII14NCT03775265
Mitomycin CMitomycin, JelmytoIII13NCT07566156
CarboplatinCarboplatine, ParaplatinII–III12NCT07129993
DocetaxelTaxotere, Beizray®III11NCT04579224
ToripalimabJS001, TeripalimabII–III10NCT07756008
Fluorouracil5-Fluorouracil, AdrucilIII9NCT07566156
AvelumabBavencio®III7NCT05092958
Sacituzumab GovitecanTrodelvy®III6NCT04579224
TislelizumabTisleizumab, TiselizumabIII5NCT06364904

Sorted by most advanced phase and number of active trials. Showing 15 of 87 drugs.

All 185 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001749 “Urinary Bladder Neoplasms”.

ItalianoFrançaisDeutsch